Trial Profile
An expanded-access trial of Trappsol Cyclo (Hydroxypropyl-betadex) in patients with Niemann-Pick Disease Type C
Status:
Recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 24 Jan 2020
Price :
$35
*
At a glance
- Drugs Hydroxypropyl betadex (Primary)
- Indications Niemann-Pick disease type C
- Focus Expanded access; Therapeutic Use
- 15 Oct 2018 According to a CTD Holdings media release, the company will broaden the expanded access program to provide the drug to Niemann Pick Disease Type C (NPC) patients in the United States who may not be eligible or unable to receive the drug via formal trials. The company is planning to re-instates the program in early 2019.
- 16 Feb 2017 Results (n=11) published in a CTD Holdings media release.
- 16 Feb 2017 According to a CTD Holdings media release, updated data from the study were presented in a poster presentation at the 13th Annual WORLDSymposium.